OBJECTIVE: Genetic modification of effector lymphocytes, such as T cells and natural killer (NK) cells, is essential for many approaches to gene-based immunotherapy of cancer. However, transduction of lymphocytes has proven difficult by currently available gene transfer methods. Previous studies have shown that chimeric fiber-modified Ad5/F35 adenoviral vectors are able to efficiently transduce hematopoietic cells including immature progenitors. In this study, we examined the gene transfer into T lymphocytes and NK cells using Ad5/F35 compared with conventional Ad5 adenovectors. METHODS: Primary T and NK cells were isolated from healthy donors' peripheral blood leukocytes by immunomagnetic selection. Cell lines and primary lymphocytes were transduced with replication-defective Ad5/F35 and Ad5, both containing a GFP reporter gene under the control of a CMV promoter. Transduction efficiencies were monitored by flow cytometry. The function of transduced lymphocytes was assessed by analysis of proliferative responses to mitogenic agents and in mixed leukocyte reactions. RESULTS: Transgene expression was detected in up to 45% of primary CD3+ T lymphocytes and in up to 60% of primary NK cells using Ad5/F35. In contrast, conventional Ad5 transduced less than 8% and 5% of primary T cells and NK cells, respectively. Transduction efficiencies were similar in CD4+ and CD8+ T lymphocytes, and transgene expression could be detected for up to seven days. Activation of T cells significantly enhanced the efficiency of Ad5/F35-mediated gene transfer. Adenoviral transduction of lymphocytes did not result in any impairment of proliferative functions. CONCLUSION: The results of this study demonstrate that both T lymphocytes and NK cells can be transduced by chimeric Ad5/F35 adenoviral vectors.
OBJECTIVE: Genetic modification of effector lymphocytes, such as T cells and natural killer (NK) cells, is essential for many approaches to gene-based immunotherapy of cancer. However, transduction of lymphocytes has proven difficult by currently available gene transfer methods. Previous studies have shown that chimeric fiber-modified Ad5/F35 adenoviral vectors are able to efficiently transduce hematopoietic cells including immature progenitors. In this study, we examined the gene transfer into T lymphocytes and NK cells using Ad5/F35 compared with conventional Ad5 adenovectors. METHODS: Primary T and NK cells were isolated from healthy donors' peripheral blood leukocytes by immunomagnetic selection. Cell lines and primary lymphocytes were transduced with replication-defective Ad5/F35 and Ad5, both containing a GFP reporter gene under the control of a CMV promoter. Transduction efficiencies were monitored by flow cytometry. The function of transduced lymphocytes was assessed by analysis of proliferative responses to mitogenic agents and in mixed leukocyte reactions. RESULTS: Transgene expression was detected in up to 45% of primary CD3+ T lymphocytes and in up to 60% of primary NK cells using Ad5/F35. In contrast, conventional Ad5 transduced less than 8% and 5% of primary T cells and NK cells, respectively. Transduction efficiencies were similar in CD4+ and CD8+ T lymphocytes, and transgene expression could be detected for up to seven days. Activation of T cells significantly enhanced the efficiency of Ad5/F35-mediated gene transfer. Adenoviral transduction of lymphocytes did not result in any impairment of proliferative functions. CONCLUSION: The results of this study demonstrate that both T lymphocytes and NK cells can be transduced by chimeric Ad5/F35 adenoviral vectors.
Authors: Ronald Benjamin; Bradford K Berges; Antonio Solis-Leal; Omoyemwen Igbinedion; Christy L Strong; Martin R Schiller Journal: Hum Genet Date: 2016-05-12 Impact factor: 4.132
Authors: Elena E Perez; Jianbin Wang; Jeffrey C Miller; Yann Jouvenot; Kenneth A Kim; Olga Liu; Nathaniel Wang; Gary Lee; Victor V Bartsevich; Ya-Li Lee; Dmitry Y Guschin; Igor Rupniewski; Adam J Waite; Carmine Carpenito; Richard G Carroll; Jordan S Orange; Fyodor D Urnov; Edward J Rebar; Dale Ando; Philip D Gregory; James L Riley; Michael C Holmes; Carl H June Journal: Nat Biotechnol Date: 2008-06-29 Impact factor: 54.908
Authors: Marcela V Maus; Joseph A Fraietta; Bruce L Levine; Michael Kalos; Yangbing Zhao; Carl H June Journal: Annu Rev Immunol Date: 2014-01-09 Impact factor: 28.527
Authors: Dawn A Maier; Andrea L Brennan; Shuguang Jiang; Gwendolyn K Binder-Scholl; Gary Lee; Gabriela Plesa; Zhaohui Zheng; Julio Cotte; Carmine Carpenito; Travis Wood; S Kaye Spratt; Dale Ando; Philip Gregory; Michael C Holmes; Elena E Perez; James L Riley; Richard G Carroll; Carl H June; Bruce L Levine Journal: Hum Gene Ther Date: 2013-03-06 Impact factor: 5.695
Authors: L Li; L N Liu; S Feller; C Allen; R Shivakumar; J Fratantoni; L A Wolfraim; H Fujisaki; D Campana; N Chopas; S Dzekunov; M Peshwa Journal: Cancer Gene Ther Date: 2009-09-11 Impact factor: 5.987